Teligent (TLGT) Upgraded to “Hold” by Zacks Investment Research
Zacks Investment Research upgraded shares of Teligent (NASDAQ:TLGT) from a sell rating to a hold rating in a research report report published on Tuesday morning.
According to Zacks, “Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey. “
Separately, Canaccord Genuity decreased their target price on shares of Teligent from $4.00 to $3.50 and set a hold rating on the stock in a research note on Friday, March 2nd. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. Teligent has a consensus rating of Hold and a consensus price target of $6.83.
Several large investors have recently modified their holdings of the company. Voya Investment Management LLC lifted its holdings in shares of Teligent by 16.1% during the second quarter. Voya Investment Management LLC now owns 23,342 shares of the company’s stock worth $214,000 after purchasing an additional 3,234 shares during the period. Northern Trust Corp lifted its holdings in shares of Teligent by 2.3% during the second quarter. Northern Trust Corp now owns 565,682 shares of the company’s stock worth $5,176,000 after purchasing an additional 12,758 shares during the period. Elk Creek Partners LLC lifted its holdings in shares of Teligent by 0.9% during the third quarter. Elk Creek Partners LLC now owns 1,709,841 shares of the company’s stock worth $11,473,000 after purchasing an additional 15,087 shares during the period. Schwab Charles Investment Management Inc. lifted its holdings in shares of Teligent by 26.1% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 74,300 shares of the company’s stock worth $270,000 after purchasing an additional 15,400 shares during the period. Finally, Parametric Portfolio Associates LLC lifted its holdings in shares of Teligent by 85.6% during the second quarter. Parametric Portfolio Associates LLC now owns 34,549 shares of the company’s stock worth $316,000 after purchasing an additional 15,933 shares during the period. Institutional investors own 68.36% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2018/03/14/teligent-tlgt-upgraded-to-hold-by-zacks-investment-research.html.
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.